When high-profile figures speak publicly about their prostate cancer, the general public health impact might be immediate. Media coverage increases awareness. More men may seek information or medical advice.
We’ve seen a recent example, with media personality Jeremy Clarkson who revealed his prostate cancer diagnosis last week. After that, A Spike Visit the Prostate Cancer UK website in men to examine in the event that they are in danger.
Other high-profile men who’ve revealed their diagnosis include writers and broadcasters. Stephen Frythe actor Ben Stiller and former US President Joe Biden.
But such publicity can even have negative points. This can reduce our perception of prostate cancer, and who might actually profit from screening and treatment.
There is a deal to create awareness.
Prostate cancer stays a The main reason Cancer deaths amongst men. And Increased focus Following a public figure who talks about his prostate cancer might help reduce the stigma surrounding men’s health and encourage discussion about symptoms.
Such public disclosures may draw attention to aggressive (fast-growing) or metastatic (spreading) prostate cancer. Men who’ve never considered prostate health could also be asked to hunt information or discuss their risk with a physician. This might be especially helpful for high-risk men.
But most prostate cancers are usually not immediately fatal. You can have heard that many men “die from prostate cancer, not from it”. This is as a result of some prostate cancers. Move so slowly They won’t ever cause symptoms or shorten life.
still, Media coverage There has at all times been an inclination to exaggerate the advantages of prostate cancer screening and never fully explain the risks and uncertainties. Celebrities are also often seen as trustworthy role models. And their personal experiences can. Shaping public perception Cancer and screening practices that are usually not fully aligned with scientific evidence.
So their stories can create a skewed impression of the person. Prostate cancer risk. This can result in over-screening, detection of very slow-growing cancers, and hasty decisions for urgent treatment that are usually not at all times needed.
To screen or not?
The principal screening test is the prostate-specific antigen (PSA) blood test. It can detect cancer earlier.
But it could actually also discover “false positives,” when high levels are usually not brought on by prostate cancer. This test can even discover essentially inoperable tumors that may never cause harm. Unnecessary investigation or treatment of those tumors can expose men to potential harm, including urinary, bowel, and sexual unwanted effects.
Prostate cancer screening using the PSA test is widely debated. And that debate has modified with the newest evidence. This includes one. A recent Cochrane reviewwhich brings together the very best available evidence.
Earlier versions of those reviews found insufficient evidence that PSA screening reduced prostate cancer mortality.
But the brand new review found that PSA-based screening likely reduces prostate cancer deaths at a population level. However, the variety of men who profit from screening is low.
It has been estimated that screening 1,000 men would lead to at least one to 2 fewer prostate cancer deaths in the long run than not screening. This reduction in mortality from screening was observed only after several years of follow-up (11–23 years within the trials included within the review). This is because many cancers detected by the PSA test are slow-growing.
Against this profit, the review found potential harms from an increased variety of men being diagnosed and treated. Out of 1,000 men, screening would mean that 16 additional men could be diagnosed and treated in comparison with no screening. Some of those men will likely be overdiagnosed and overtreated for cancers that might not cause harm in the event that they were undetected.
Overall, the review didn’t conclude that each man must have a PSA test. It found that while screening can reduce the prospect of dying from prostate cancer, it could actually also result in unnecessary tests and coverings.
The profit balance of potential losses will also be easily shifted. This occurs when men are unlikely to learn from frequent screening (with over-diagnosis and over-treatment), or insufficiently frequent screening of high-risk men (with under-diagnosis and under-treatment).
All of this could come at a substantial cost to each individuals and the health system.
New advice
New evidence included in Cochrane reviews is resulting in updated clinical guidelines in lots of countries, including Australia and the UK.
Revised Draft Australian Guidelines This is more likely to suggest that men who ask for testing should first learn of the advantages and harms. The draft guidelines also include targeted recommendations for specific groups.
UK National Screening Committee Recommends A more targeted offer only to men aged 45-61 who’ve a particular genetic mutation (BRCA2 gene) and a family history of breast, ovarian, pancreatic or prostate cancer.
Both of those guidelines support a shared decision-making approach. This is where men are encouraged to debate their age, family history, overall health, personal values ​​and tolerance for uncertainty with their healthcare provider before making a choice. The PSA test.
Both guidelines advise against widespread, population-wide screening.
So what next?
Decisions about prostate cancer screening are complex. Men should weigh each the professionals and cons of every step, from PSA testing to possible treatment.
The latest evidence suggests that PSA screening may avoid wasting lives, however the profit is modest and comes with significant trade-offs.
Celebrity stories ought to be the start line for an informed conversation. Public awareness is worthwhile when it results in informed decision-making, not when it replaces it.